[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623771":3},{"organization":4,"armGroups":7,"interventions":35,"overallOfficials":53,"centralContacts":57,"locations":63,"responsibleParty":80,"collaborators":40,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":40,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":40,"enrollmentInfo":91,"targetDuration":40,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":66,"whyStopped":40,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Glaukos Corporation","INDUSTRY",[8,14,19,24,29],{"label":9,"type":10,"description":11,"interventionNames":12},"GLK-321 low dose BID","EXPERIMENTAL","Low dose of GLK-321 administered twice daily (BID) to both eyes",[13],"Drug: GLK-321 low dose BID",{"label":15,"type":10,"description":16,"interventionNames":17},"GLK-321 mid dose BID","Mid dose of GLK-321 administered twice daily (BID) to both eyes",[18],"Drug: GLK-321 mid dose BID",{"label":20,"type":10,"description":21,"interventionNames":22},"GLK-321 high dose BID","High dose of GLK-321 administered twice daily (BID) to both eyes",[23],"Drug: GLK-321 high dose BID",{"label":25,"type":10,"description":26,"interventionNames":27},"GLK-321 high dose QD","High dose of GLK-321 administered once daily (QD) to both eyes",[28],"Drug: GLK-321 high dose QD",{"label":30,"type":31,"description":32,"interventionNames":33},"Placebo BID","PLACEBO_COMPARATOR","Placebo administered twice daily (BID) to both eyes",[34],"Drug: Placebo BID",[36,41,44,47,50],{"type":37,"name":9,"description":38,"armGroupLabels":39,"otherNames":40},"DRUG","Twice daily administration of low dose GLK-321 to both eyes",[9],null,{"type":37,"name":15,"description":42,"armGroupLabels":43,"otherNames":40},"Twice daily administration of mid dose GLK-321 to both eyes",[15],{"type":37,"name":20,"description":45,"armGroupLabels":46,"otherNames":40},"Twice daily administration of high dose GLK-321 to both eyes",[20],{"type":37,"name":25,"description":48,"armGroupLabels":49,"otherNames":40},"Once daily administration of high dose GLK-321 to both eyes",[25],{"type":37,"name":30,"description":51,"armGroupLabels":52,"otherNames":40},"Twice daily administration of placebo to both eyes",[30],[54],{"name":55,"affiliation":5,"role":56},"Study Director, MD","STUDY_DIRECTOR",[58],{"name":59,"role":60,"phone":61,"phoneExt":40,"email":62},"Study Manager","CONTACT","949-739-8749","ClinicalResearch@Glaukos.com",[64],{"facility":65,"status":66,"city":67,"state":68,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":78},"Glaukos Clinical Study Site","RECRUITING","Newport Beach","California","92663","United States","US",{"type":73,"coordinates":74},"Point",[75,76],-117.92895,33.61891,{"lat":76,"lon":75},[79],{"name":59,"role":60,"phone":61,"phoneExt":40,"email":62},{"type":81,"investigatorFullName":40,"investigatorTitle":40,"investigatorAffiliation":40,"oldNameTitle":40,"oldOrganization":40},"SPONSOR","100623771","phase-2-evaluation-of-the-safety-and-efficacy-of-glk-321-in-subjects-with-demodex-blepharitis-100623771",false,"NCT07400965","Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis","Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis","Inclusion Criteria:\n\n* Signs of Demodex blepharitis in at least one eye\n* Best Spectacle Corrected Visual Acuity (BSCVA) of 20\u002F80 Snellen or better in each eye\n\nExclusion Criteria:\n\n* Presence of eczema or dermatitis in the ocular region of either eye\n* Use of lid hygiene products within 14 days of Screening\n* Active ocular infection or inflammation, other than blepharitis, in either eye at Screening\n* Women who are pregnant, planning a pregnancy, or nursing\n* Have used an investigational drug or device within 30 days prior to Screening or concurrently enrolled in another investigational drug or device trial","ALL","18 Years",{"count":92,"type":93},250,"ESTIMATED","INTERVENTIONAL",[96],"PHASE2","This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.",[99],"Demodex Blepharitis",[101],"demodex blepharitis","2026-02-24",{"date":104,"type":105},"2026-02-27","ACTUAL",{"date":107,"type":105},"2025-12-05",{"date":109,"type":93},"2026-11",{"name":5,"class":6},1]